Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
10 hedge funds and large institutions have $957K invested in Hepion Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
154% more capital invested
Capital invested by funds: $377K → $957K (+$580K)
150% more funds holding
Funds holding: 4 → 10 (+6)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$236K |
| 2 |
Renaissance Technologies
New York
|
+$166K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$65.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.2K |
| 5 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$50.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$278K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$46K |
| 3 |
VF
Virtu Financial
New York
|
-$11.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $325K | +$236K | +61 | New |
|
|
2
Renaissance Technologies
New York
| $231K | +$166K | +43 | New |
|
|
OAM
3
Oxford Asset Management
Oxford,
United Kingdom
| $92K | +$65.8K | +17 | New |
|
|
VF
4
Virtu Financial
New York
| $79K | -$11.6K | -3 | -17% |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $74K | +$54.2K | +14 | New |
|
|
PFS
6
Prospera Financial Services
Dallas,
Texas
| $70K | +$50.3K | +13 | New |
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $37K | +$27.1K | +7 | New |
|
8
Morgan Stanley
New York
| $19K | +$15.5K | +4 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $18K | -$3.87K | -1 | -25% |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $10.7K | +$7.74K | +2 | New |
|
|
SFS
11
Sowell Financial Services
North Little Rock,
Arkansas
| $1K | – | – | – |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$278K | -115 | Closed |
|
|
ARTA
13
A.R.T. Advisors
New York
| – | -$46K | -19 | Closed |
|
HEPA Hedge Fund Activity: Q4 2019 in Review
10 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2019, worth a combined $957K — up 154% from $377K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HEPA positions and 2 closed out — a net gain of 6 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $236K. The largest seller was Sabby Management, exiting entirely with an estimated $278K sold.
- 10 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2019, up from 4 in Q3 2019.
- Funds reported $957K of Hepion Pharmaceuticals stock for Q4 2019, up 154% quarter-over-quarter.
- 8 funds opened new Hepion Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of +6 holders.
- The largest Hepion Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $236K added.
- The largest Hepion Pharmaceuticals seller in Q4 2019 was Sabby Management, an estimated $278K sold.
Based on aggregated 13F filings for Q4 2019.